Adjuvant Capital overview
Stories about Adjuvant Capital
Adjuvant Capital leads Series A round for 54gene
54gene, an African genomics research, services and development company, has raised $15 million in Series A funding.
Themis raises 40 mln euros
Themis said Sept. 18 that it raised 40 million euros ($44 million) in a Series D round of funding co-led by new investors, Farallon Capital and Hadean Ventures. MSD (tradename of Merck & Co Inc, Kenilworth NJ USA) and Adjuvant Capital, as well as current investors Global Health Investment Fund, aws Gruenderfonds, Omnes Capital, Ventech and Wellington Partners Life Sciences, also participated. Themis develops immunomodulation therapies for infectious diseases and cancer.
InDevR pulls in $7 mln Series A
Boulder, Colorado-based InDevR Inc, a biotechnology company, has raised $7 million in Series A funding. The investor was Adjuvant Capital.
Adjuvant Capital contact information
Offices
500 5th Avenue Suite 4000, New York, 10110, United StatesContacts
| Name | Job title | Location | |
|---|---|---|---|
Key Contact Mr. Glenn Rockman | Job titleFounder and Managing Partner | LocationNew York, United States | Email  ---------- |
| Mr. Kabeer Aziz | Job titleCo-Founder and Partner | LocationNew York, United States | Email ---------- |
| Ms. Alexandra (Sandra) Glucksmann | Job titleAdvisory Partner | LocationNew York, United States | Email ------ |
| Mr. Gerard Cunningham | Job titleOperating Partner | LocationNew York, United States | Email ----- |
Adjuvant Capital funds managed
Closed funds: 1
| Fund | Fund size | Close date | Strategy |
|---|---|---|---|
Fund size ------- | Close dateFeb 2021 | Strategy ----------- | |
Stories that mention Adjuvant Capital
Frontier Nutrition pulls in $6m Series B
Frontier Nutrition, an India-based maker of fortified snacks, has raised $6 million in Series B financing.
MinervaX attracts $57m Series B
MinervaX, a Danish biotechnology company, has raised $57 million in Series B financing.
MSD to buy VC-backed Themis
MSD has agreed to acquire Vienna-based Themis, a provider of immunomodulation therapies for infectious diseases and cancer.
ChromaCode scores $10m
ChromaCode Inc, a software and reagent technology company, has secured $10 million in a Series C extension.
Codagenix lands $20 mln Series B
Farmingdale, New York-based Codagenix Inc, a developer of prophylactic vaccines and oncolytic virus therapies, has raised $20 million in Series B funding.
AN2 Therapeutics scores $12 mln Series A
California-based AN2 Therapeutics Inc, a biopharmaceutical company focused on infectious diseases, has raised $12 million in Series A financing. Mountain Group Partners led the round with participation from Adjuvant Capital, Brii Biosciences and BioRock Ventures.
AN2 Therapeutics scores $12 mln Series A
California-based AN2 Therapeutics Inc, a biopharmaceutical company focused on infectious diseases, has raised $12 million in Series A financing. Mountain Group Partners led the round with participation from Adjuvant Capital, Brii Biosciences and BioRock Ventures.
X-Vax rakes in $56 mln
Jupiter, Florida-based X-Vax Technology Inc, a herpes vaccines developer, has raised $56 million in funding. The investors included Johnson & Johnson Innovation – JJDC, Inc., Adjuvant Capital, Serum Institute of India, Alexandria Venture Investments and FF DSF VI.